Mesothelin targeted cancer immunotherapy for patients

2021 Fiscal Year Final Research Report

• Project/Area Number: 18K15295
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 50020:Tumor diagnostics and therapeutics-related
• Research Institution: National Defense Medical College
• Principal Investigator: Einama Takahiro 防衛医科大学校(医学教育部医学科進学課程及び専門課程、動物実験施設、共同利用研究施設、病院並びに防衛, 外科学, 講師 (70421964)
• Project Period (FY): 2018-04-01 – 2022-03-31
• Keywords: Mesothelin / 膵癌 / 抗体治療 / CA125

Outline of Final Research Achievements

Our aim was to proceed Mesothelin targeted immunotherapy.
We showed that mesothelin antibody made cell to cell adhesions lost their function and increased chemotherapy effect for mesothelin positive cells.
And we have reported that mesothelin and CA125 co-expression existed in pancreatic cancer, IPMN, breast cancer, biriary tract cancer and cervical cancer.

Free Research Field

膵癌

Academic Significance and Societal Importance of the Research Achievements

Mesothelinは膵癌、肺癌、卵巣癌などの難治性癌に多く発生しており、抗Mesothelin治療を行うことでこれらの難治性癌の予後が延長する可能性がある。
本研究成果は動物実験において証明され、さらに人への応用される可能性のあるものである。